KLRK1 and central nervous system cancer: Notably, the combination of NKG2D‐based CAR‐T cells with subtherapeutic doses of radiotherapy enhanced CAR‐T cell migration and effector functions, providing a strong rationale for translating this approach into human patients with glioma [101].